The effect of vaginal Danazol in the management of uterine hemorrhage during and post operative hysteroscopy

Not Applicable

• Conditions: abnormal uterine and vaginal bleeding.; Absent, scanty and rare menstruation, Excessive, frequent and irregular menstruation, Other abnormal uterine and vaginal bleeding; N91, N92,

• Registration Number: IRCT201307305283N8
• Lead Sponsor: Tabriz University of Medical Sciences, Vice chancellor for Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 144

Inclusion Criteria

Women in reproductive age with moderate abnormal uterine bleeding which is resistant to drugs, caused by endometrial hyperplasia; endometrial polyps; submucosal myomas less than 4 cm in size.
Exclusion criteria: Patients with Heart, Lung, Renal, Liver disease; Patients with metabolic disease like hypertension, hyperlipidemia, hyperglycemia; Patients with cervical cancers; uterine cancers; submucosal myomas larger than 4 cm in size; Uterine septum; Pregnant women; Patients with genial tract infections; Patients using Anti coagulant drugs; Patients with sever uterine bleeding.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Amount of bleeding during operative hysteroscopy. Timepoint: one and two month after administration of Danasol and Diphereline respectively. Method of measurement: visual scale (0-5).

Secondary Outcome Measures

Name	Time	Method
Duration of hysteroscopy. Timepoint: one and two month after administration of Danasol and Diphereline respectively. Method of measurement: minutes measured by chronometer.;Post operative bleeding. Timepoint: in 24 hour after hysteroscopy. Method of measurement: visual scale (0-5).